Impact of ABO-incompatibility on hepatocellular carcinoma recurrence after living donor liver transplantation.

European Journal of Surgical Oncology（2019）

引用 10|浏览6

暂无评分

摘要

ABO-I LDLT, having no adverse impact on oncological outcomes, can be a feasible transplant option for HCC.

查看译文

关键词

Hepatocellular carcinoma,Rituximab,ABO-Incompatibility,Living donor liver transplantation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要